Sponsored Content by BenchlingReviewed by Ify IsiborJul 14 2026
Ori Biotech, a prominent entity based in London and New Jersey, leads in cell and gene therapy (CGT) manufacturing technology. This organization has created a proprietary, full-stack manufacturing platform designed to facilitate broad patient access to a new era of individualized, lifesaving treatments.
Through the complete automation and standardization of CGT manufacturing within a closed system, Ori Biotech presents therapeutic developers with the capacity to smoothly transition from preclinical process development to large-scale commercial production.
Image Credit: Shutterstock.com/Nemes Laszlo
Reduction in planning time between process runs
Ori Biotec’s technology improves efficiency in data handling and analysis and enables research teams to draw conclusions, formulate hypotheses, and conduct follow-on experiments at a faster rate.
Reduction in data entry errors
Automation enhances efficiency by reducing human error, improving scalability for larger volume production, and strengthening quality control for consistent, reliable outcomes.
Reduction in experimental workload
Standardized data capture enables easy access to information across multiple experiments, allowing researchers to perform meta-analyses and gain insights that might otherwise be missed.
Challenges with cell and gene therapy process development
Cell and Gene Therapy (CGTs) are transforming disease treatment modalities.
However, multiple hindrances in process development impede scaling capabilities and restrict widespread patient availability of these critical therapies.
The overwhelming majority of CGT process development tasks rely on manual documentation, spreadsheets, and discrete digital tools that struggle to match the pace of scientific advancement. This results in several significant difficulties:
Process execution
- Unstructured process and analytical data capture
- Lack of real-time process visibility
- Hampered communication within and across groups
Process optimization
- Manual, labor-intensive data analysis and data management prone to human error
- Challenging to search and aggregate historical data to perform meta-analysis
Modernizing cell and gene therapy process development through 'Biology + Engineering + Digital' innovation
Ori Biotech is addressing opportunities to enhance the established CGT process development methodologies by providing a platform intended to promote widespread accessibility to next-generation cell and gene therapies.
Their approach is founded on three core tenets: a deep understanding and execution of exceptional biology, the strategic use of automation, and the establishment of a digitally native system.
Source: Benchling
| Ori Biotech’s Goal #1 |
Solution with Benchling |
Enhance biological efficiency
Consistent and robust biological performance is the foundation of CGT process development. Ori Biotech is working to improve product quality and reduce costs by optimizing quality attributes, improving efficacy and potency, and supporting a wide variety of development processes. |
Increase biological throughput
Ori Biotech leverages the Benchling R&D Cloud to better track data from experimentation with multiple cell types. This helps them scale the biological throughput of their platform. The two specific ways by which Ori Biotech achieves this are: |
- Improve biological performance: Ori Biotech is introducing unique platform-specific techniques that speed up achieving clinically relevant doses, enhance transduction efficiency, provide process adaptability, and ultimately decrease cost and vein-to-vein time.
|
- Track assays and experiments linked to specific donor lots: As Ori Biotech investigates newer methods and assays to boost biological efficiency, they use Benchling R&D Cloud to link all these assays, variables and experimental data back to the starting donor ID automatically. As a result, Ori Biotech can now study donor characteristics and optimize biological performance faster.
|
- Retain biological flexibility: Most current approved cell and gene therapies (CGTs) focus on Chimeric Antigen Receptors (CARs) and T-cells. However, as personalized medicine and technology progress, more diverse cell types will be used to create new treatments. Ori Biotech is already positioned for this demand, as its platform is primed to offer the necessary flexibility to adapt to multiple cell types.
|
- Set up customizable templates and configurations to support multiple cell type: Ori Biotech creates experiment templates and registry hierarchies that work not just for current CAR and T-cell workflows, but can also be customized to support other cell types such as NKs and TILs. Thus Ori Biotech can study multiple cell types simultaneously as needed without affecting throughput.
|
Outcomes:
Time saved on data management
By optimizing data capture and providing researchers with standardized templates, Ori Biotech was able to reduce the time researchers spend capturing and analyzing experimental data. |
Increase in data quality
By using standardized templates, Ori Biotech has seen a reduction in data handling time and eliminated the potential for data transcription errors as they scaled up. |
| Ori Biotech's Goal #2 |
Solution with Benchling |
Optimize process development
While optimizing biology is usually the first step – the science and the processes must work together. Ori Biotech's goal is to reduce process development timeline with automation, reduce costs by increasing throughput while minimizing manual labor, and ensure quality through process consistency. |
Ensure process consistency and success
Ori Biotech uses the Benchling R&D Cloud to standardize and automate their processes to reduce process variability and minimize manual inconsistencies. The two specific ways by which Ori Biotech does this are: |
- Reduce process variability: Variability in the starting donor material for CGT, especially autologous therapies, combined with process variability means achieving a consistent and robust manufacturing process is challenging. Ori Biotech's goal is to systematically address inherent process variability to ensure a consistent product from their platform.
|
- Standardize process data capture across runs and sites: Ori Biotech maps their unit operations onto Benchling with structured input parameters, run templates, and results tables. This ensures that scientists across multiple sites can collaborate effectively, execute process runs consistently, and capture usable data.
|
- Minimize manual labor and process deviations: Most of the process development unit operations are highly manual, with technique playing a significant role in process outcomes. Ori Biotech's goal is to automate processes to remove manual work, increase consistency and reduce human errors.
|
- Automate data capture from equipment and instruments: Ori Biotech uses Benchling to ingest captured data from their analytical instruments. This allows them to import data faster and with higher accuracy than manual data entry.
|
Outcomes:
Faster, more accurate data capture
Ori Biotech reduced the time taken to enter process data through data entry standardization in Benchling. |
Improved data Interoperability
Ori Biotech reduced the potential need for data transcription or data entry due to the ingestion of captured data from their analytical instruments. |
| Ori Biotech’s Goal #3 |
Solution with Benchling |
Create a digitally-native platform
For Ori Biotech, data is an operational tool that helps their teams characterize and understand their manufacturing platform. Thus, Ori Biotech created a platform that is digitally and cloud native, ready for Bioprocessing 4.0, and provides the advanced analytics necessary to reduce timelines, cut process development costs, and improve product quality. |
Drive efficiency with digitization
Ori Biotech uses Benchling to centralize data from multiple sources and analyze data to improve the performance of their manufacturing platform. Two ways by which Ori Biotech attains this are: |
- Ready for Bioprocessing 4.0: A lot of newer technologies (IoT, Cloud) and SaaS IT systems (next-generation MES, QMS, LIMS) are disrupting CGT process development. Ori Biotech's goal is to create a platform that treats data as a first-class citizen, ensuring its integrity, security, and accessibility as well as integrating with external technologies and systems.
|
- Democratize data access: Ori Biotech centralizes all their experimental and equipment data across teams and sites on Benchling. As a result, all data is now findable, accessible, interoperable, and reusable for Bioprocessing 4.0 applications.
|
- Improve platform performance with data analysis: Traditional data management practices with spreadsheets did not meet Ori Biotech's data goals and scaling needs. They wanted to create a platform with improved data access that would support data analysis, including machine learning and statistical analysis.
|
- Enable meta analysis: Ori Biotech uses Benchling’s data warehouse to capture structured experimental data and all related metadata. This allows them to run sophisticated meta analysis by experiment ID or run ID to improve their platform performance. Additionally, the data warehouse also provides a data foundation for future ML and AI applications.
|
Outcomes:
Faster time to milestone
Ori Biotech can now optimize processes with fewer process runs than previously possible because of FAIR data access and meta-analysis possible with Benchling. |
Improved scientist efficiency
By reducing the time researchers spend analyzing experimental data or performing low-value tasks, Ori Biotech reduced equipment downtime. |
Conclusions
The delivery of safe and effective CGTs to patients hinges upon efficient, scalable, and adaptable process development.
Spreadsheets and other isolated solutions are inadequate for keeping pace with scientific innovation. CGT enterprises require a contemporary digital solution that can scale and evolve.
Ori Biotech’s manufacturing platform, in conjunction with Benchling, advances innovation across the three crucial domains of biology, engineering, and data. Researchers can now shorten planning intervals between process cycles, minimize data input inaccuracies, and reduce experimental effort. This leads to superior product quality, reduced expenses, diminished process development timelines, and increased process uniformity.
This advanced manufacturing platform will assist therapeutic developers in accelerating the market introduction of life-saving products and ensuring broad patient access.
About Benchling
Benchling makes biotech research and development faster and more collaborative. Biotechnology has the potential to solve humanity’s most pressing challenges, such as disease, renewable energy, clean water, and hunger. The brightest minds are working on these problems but they are equipped with archaic tools. We aspire to fix this and increase the rate of scientific output with a web-based platform that allows researchers to design and run experiments, analyze data, and share results.
Hundreds of thousands of scientists all around the world use Benchling to do research. Whether they are at the world’s largest companies, the top research universities, or working on a startup in a garage, scientists use Benchling for the same reason: to be empowered, not encumbered, by their tools.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.net, which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.